ISSN 1662-4009 (online)

ey0021.10-4 | Important for Clinical Practice | ESPEYB21

10.4. Demographic, clinical, management, and outcome characteristics of 8,004 young children with type 1 diabetes

JL Sandy , SR Tittel , S Rompicherla , B Karges , S James , N Rioles , et al.

Brief Summary: This observational study highlights the challenges of managing T1D in 8,004 young children with type 1 diabetes (T1D) (age < 6 years) from 3 international registries: Diabetes Prospective Follow-Up Registry (DPV), T1D Exchange Quality Improvement Network (T1DX-QI), and the Australasian Diabetes Data Network (ADDN), using data collected between 2019 and 2021. More than half of included children did not achieve the recommended HbA1c target < 7.0% (53 mmol/...

ey0015.10-8 | Continuous glucose monitoring, insulin pumps and artificial pancreas | ESPEYB15

10.8 Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with T1DM

B Karges , A Schwandt , B Heidtmann , O Kordonouri , E Binder , U Schierloh , C Boettcher , T Kapellen , J Rosenbauer , RW Holl

To read the full abstract: JAMA. 2017;318:1358-1366Here, the authors compared the metabolic control in young patients with T1DM with insulin pump therapies versus multiple injection treatment modalities using the data from 30 579 patients younger than 20 years of age of 446 centers in a prospective population-based cohort study. While it is very clear that pump therapy, compared with injection ...

ey0020.8-6 | Important for Clinical Practice | ESPEYB20

8.6. Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study

B Karges , SR Tittel , A Bey , C Freiberg , C Klinkert , O Kordonouri , S Thiele-Schmitz , C Schroder , C Steigleder-Schweiger , RW Holl

Brief summary: In this large registry-based study, including 32 117 children and young people (aged 1.5–25 years) with type 1 diabetes (T1D), the use of continuous glucose monitoring (CGM) was associated with decreased rates of diabetic ketoacidosis (DKA) and severe hypoglycemia. Of interest, some CGM metrics predicted risk for these complications.CGM systems are now widely used by children with T1D, and there is evidence both from clinical trials a...